KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Guardant Health (GH) EBITDA Margin (2017 - 2025)

Guardant Health's EBITDA Margin history spans 9 years, with the latest figure at 42.95% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 1947.0% year-over-year to 42.95%; the TTM value through Dec 2025 reached 44.53%, up 1550.0%, while the annual FY2025 figure was 44.53%, 1550.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 42.95% at Guardant Health, down from 37.33% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 37.33% in Q3 2025 and bottomed at 137.12% in Q1 2021.
  • The 5-year median for EBITDA Margin is 89.03% (2021), against an average of 87.58%.
  • The largest annual shift saw EBITDA Margin plummeted -8540bps in 2021 before it skyrocketed 6497bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 90.84% in 2021, then decreased by -27bps to 115.15% in 2022, then decreased by -11bps to 127.38% in 2023, then soared by 51bps to 62.42% in 2024, then surged by 31bps to 42.95% in 2025.
  • Per Business Quant, the three most recent readings for GH's EBITDA Margin are 42.95% (Q4 2025), 37.33% (Q3 2025), and 45.85% (Q2 2025).